Literature DB >> 9783750

Crystal structure of botulinum neurotoxin type A and implications for toxicity.

D B Lacy1, W Tepp, A C Cohen, B R DasGupta, R C Stevens.   

Abstract

Botulinum neurotoxin type A (BoNT/A) is the potent disease agent in botulism, a potential biological weapon and an effective therapeutic drug for involuntary muscle disorders. The crystal structure of the entire 1,285 amino acid di-chain neurotoxin was determined at 3.3 A resolution. The structure reveals that the translocation domain contains a central pair of alpha-helices 105 A long and a approximately 50 residue loop or belt that wraps around the catalytic domain. This belt partially occludes a large channel leading to a buried, negative active site--a feature that calls for radically different inhibitor design strategies from those currently used. The fold of the translocation domain suggests a mechanism of pore formation different from other toxins. Lastly, the toxin appears as a hybrid of varied structural motifs and suggests a modular assembly of functional subunits to yield pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783750     DOI: 10.1038/2338

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  220 in total

1.  Translocation of the catalytic domain of diphtheria toxin across planar phospholipid bilayers by its own T domain.

Authors:  K J Oh; L Senzel; R J Collier; A Finkelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor.

Authors:  J Herreros; G Lalli; G Schiavo
Journal:  Biochem J       Date:  2000-04-01       Impact factor: 3.857

3.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

Review 4.  Tetanus.

Authors:  J J Farrar; L M Yen; T Cook; N Fairweather; N Binh; J Parry; C M Parry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

5.  Structure and stability effects of mutations designed to increase the primary sequence symmetry within the core region of a beta-trefoil.

Authors:  S R Brych; S I Blaber; T M Logan; M Blaber
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

6.  Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Authors:  B P Mullaney; M G Pallavicini; J D Marks
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin.

Authors:  Tzuu-Wang Chang; Michael Blank; Pavithra Janardhanan; Bal Ram Singh; Charlene Mello; Michael Blind; Shuowei Cai
Journal:  Biochem Biophys Res Commun       Date:  2010-05-07       Impact factor: 3.575

8.  Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.

Authors:  Abby R Kroken; Andrew P-A Karalewitz; Zhuji Fu; Jung-Ja P Kim; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-06-01       Impact factor: 5.157

9.  Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A.

Authors:  Cindi R Corbett; Erin Ballegeer; Kelly A Weedmark; M D Elias; Fetweh H Al-Saleem; Denise M Ancharski; Lance L Simpson; Jody D Berry
Journal:  Hybridoma (Larchmt)       Date:  2011-12

10.  Accommodation of a highly symmetric core within a symmetric protein superfold.

Authors:  Stephen R Brych; Jaewon Kim; Timothy M Logan; Michael Blaber
Journal:  Protein Sci       Date:  2003-12       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.